Revenue growth has slowed toward mid-single digits, with 2026Q3 revenue of $19.8B up only 3.6% and net margin of 8.0% versus 8.8% a year earlier, suggesting modest margin pressure.
HCA Healthcare, Inc. (HCA) annual income statement — 30-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Sales/Revenue | 78.7B | 75.6B | 70.6B | 64.97B | 60.23B | 58.75B | 51.53B | 51.34B | 46.68B | 43.61B | 41.49B | 39.68B | 36.92B | 34.18B | 33.01B | 32.51B | 30.68B | 30.05B | 28.37B | 26.86B | 25.48B | 24.45B | 23.5B | 21.81B | 19.73B | 17.95B | 16.67B | 16.66B | 18.68B | 18.82B | 19.91B |
| Revenue Growth % | 5.82% | 7.08% | 8.67% | 7.86% | 2.52% | 14.01% | 0.38% | 9.98% | 7.02% | 5.12% | 4.57% | 7.48% | 8% | 3.54% | 1.56% | 5.94% | 2.1% | 5.91% | 5.64% | 5.42% | 4.18% | 4.06% | 7.77% | 10.54% | 9.89% | 7.7% | 0.08% | -10.83% | -0.73% | -5.47% | 12.51% |
| Cost of Goods Sold | 61.63B | 44.23B | 41.92B | 39.39B | 37.06B | 36.26B | 8.37B | 8.48B | 7.72B | 7.32B | 6.93B | 6.64B | 6.26B | 5.97B | 5.72B | 5.18B | 4.96B | 4.87B | 4.62B | 4.39B | 4.32B | 4.13B | 3.9B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.54B |
| COGS % of Revenue | - | 58.5% | 59.38% | 60.63% | 61.52% | 61.72% | 16.24% | 16.52% | 16.55% | 16.77% | 16.71% | 16.73% | 16.96% | 17.47% | 17.32% | 15.93% | 16.17% | 16.2% | 16.28% | 16.36% | 16.96% | 16.87% | 16.6% | - | - | - | - | - | - | - | 37.87% |
| Gross Profit | 17.07B | 31.37B | 28.68B | 25.58B | 23.18B | 22.49B | 43.16B | 42.85B | 38.95B | 36.3B | 34.56B | 33.04B | 30.66B | 28.21B | 27.3B | 24.5B | 23.07B | 25.18B | 23.75B | 22.46B | 21.16B | 20.33B | 19.6B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.25B |
| Gross Margin % | 21.69% | 41.5% | 40.62% | 39.37% | 38.48% | 38.28% | 83.76% | 83.48% | 83.45% | 83.23% | 83.29% | 83.27% | 83.04% | 82.53% | 82.68% | 75.38% | 75.2% | 83.8% | 83.72% | 83.64% | 83.04% | 83.13% | 83.4% | - | - | - | - | - | - | - | 56.49% |
| Gross Profit Growth % | - | 9.4% | 12.12% | 10.36% | 3.05% | -47.89% | 0.72% | 10.02% | 7.31% | 5.04% | 4.59% | 7.78% | 8.66% | 3.36% | 11.4% | 6.19% | -8.38% | 6.02% | 5.75% | 6.18% | 4.06% | 3.71% | - | - | - | - | - | - | - | -100% | 8.14% |
| Operating Expenses | 5B | 19.41B | 18.13B | 15.95B | 14.12B | 12.81B | 35.9B | 35.64B | 32.31B | 30.24B | 28.36B | 27.07B | 25.09B | 23.42B | 22.48B | 20.16B | 18.91B | 21.38B | 20.82B | 19.51B | 18.32B | 17.43B | 16.89B | 19.01B | 17.68B | 15.73B | 117M | 220M | 1.79B | 17.65B | 8.35B |
| OpEx % of Revenue | - | 25.67% | 25.68% | 24.55% | 23.45% | 21.81% | 69.67% | 69.42% | 69.22% | 69.34% | 68.35% | 68.24% | 67.96% | 68.52% | 68.09% | 62.03% | 61.63% | 71.15% | 73.37% | 72.65% | 71.9% | 71.25% | 71.84% | 87.17% | 89.61% | 87.61% | 0.7% | 1.32% | 9.58% | 93.78% | 41.93% |
| Selling, General & Admin | 24.43B | 8B | 31.17B | 29.49B | 27.68B | 26.78B | 23.87B | 23.56B | 21.43B | 20.06B | 18.9B | 18.11B | 16.64B | 15.65B | 15.09B | 13.44B | 12.48B | 11.96B | 11.44B | 10.71B | 10.41B | 9.93B | 9.42B | 8.68B | 7.95B | 7.28B | 6.64B | 6.75B | 7.81B | 7.63B | 7.21B |
| SG&A % of Revenue | - | 10.58% | 44.15% | 45.39% | 45.96% | 45.58% | 46.33% | 45.89% | 45.9% | 45.99% | 45.55% | 45.66% | 45.08% | 45.77% | 45.71% | 41.35% | 40.69% | 39.79% | 40.32% | 39.89% | 40.86% | 40.6% | 40.08% | 39.81% | 40.31% | 40.54% | 39.83% | 40.52% | 41.81% | 40.55% | 36.19% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -2M | 11.41B | -13.04B | -13.54B | -13.56B | -13.96B | 12.03B | 12.08B | 10.89B | 10.18B | 9.46B | 8.96B | 8.45B | 7.77B | 7.39B | 6.72B | 6.42B | 9.43B | 9.38B | 8.8B | 7.91B | 7.5B | 7.47B | 10.33B | 9.73B | 8.45B | -6.52B | -6.53B | -6.02B | 10.02B | 1.14B |
| Operating Income | 12.07B | 11.96B | 10.55B | 9.63B | 9.05B | 9.68B | 7.26B | 7.22B | 6.64B | 6.06B | 6.2B | 5.96B | 5.57B | 4.79B | 4.82B | 4.34B | 4.17B | 3.8B | 2.94B | 2.95B | 2.84B | 2.9B | 2.72B | 2.8B | 2.05B | 2.23B | 16.55B | 16.44B | 16.89B | 1.17B | 2.9B |
| Operating Margin % | 15.34% | 15.83% | 14.94% | 14.82% | 15.03% | 16.47% | 14.09% | 14.06% | 14.23% | 13.89% | 14.94% | 15.03% | 15.07% | 14.02% | 14.59% | 13.35% | 13.57% | 12.65% | 10.34% | 10.99% | 11.13% | 11.87% | 11.56% | 12.83% | 10.39% | 12.39% | 99.3% | 98.68% | 90.42% | 6.22% | 14.56% |
| Operating Income Growth % | - | 13.44% | 9.56% | 6.34% | -6.46% | 33.27% | 0.61% | 8.67% | 9.66% | -2.27% | 3.91% | 7.19% | 16.13% | -0.5% | 11.02% | 4.15% | 9.58% | 29.51% | -0.58% | 4.09% | -2.34% | 6.92% | -2.9% | 36.51% | -7.91% | -86.56% | 0.71% | -2.69% | 1342.53% | -59.59% | 9.61% |
| EBITDA | 15.81B | 15.49B | 13.86B | 12.7B | 12.02B | 12.53B | 9.98B | 9.81B | 8.92B | 8.19B | 8.16B | 7.87B | 7.38B | 6.54B | 6.5B | 5.8B | 5.59B | 5.23B | 4.35B | 4.38B | 4.23B | 4.28B | 3.97B | 3.91B | 3.06B | 3.27B | 17.59B | 17.53B | 18.14B | 2.41B | 4.05B |
| EBITDA Margin % | 20.09% | 20.49% | 19.63% | 19.55% | 19.96% | 21.33% | 19.37% | 19.12% | 19.11% | 18.77% | 19.68% | 19.83% | 20% | 19.15% | 19.67% | 17.85% | 18.21% | 17.39% | 15.33% | 16.3% | 16.59% | 17.49% | 16.88% | 17.92% | 15.51% | 18.23% | 105.49% | 105.25% | 97.1% | 12.8% | 20.36% |
| EBITDA Growth % | 4.7% | 11.75% | 9.09% | 5.67% | -4.06% | 25.52% | 1.72% | 10.02% | 8.94% | 0.29% | 3.75% | 6.55% | 12.83% | 0.77% | 11.92% | 3.88% | 6.89% | 20.11% | -0.62% | 3.57% | -1.19% | 7.87% | 1.46% | 27.79% | -6.54% | -81.39% | 0.31% | -3.35% | 652.97% | -40.56% | 11.81% |
| D&A (Non-Cash Add-back) | 3.74B | 3.52B | 3.31B | 3.08B | 2.97B | 2.85B | 2.72B | 2.6B | 2.28B | 2.13B | 1.97B | 1.9B | 1.82B | 1.75B | 1.68B | 1.47B | 1.42B | 1.43B | 1.42B | 1.43B | 1.39B | 1.37B | 1.25B | 1.11B | 1.01B | 1.05B | 1.03B | 1.09B | 1.25B | 1.24B | 1.16B |
| EBIT | 12.16B | 12.08B | 10.58B | 9.64B | 10.32B | 11.4B | 7.01B | 7.07B | 7.09B | 6.07B | 6.52B | 5.62B | 5.22B | 4.79B | 4.69B | 5.6B | 4.33B | 3.99B | 3.19B | 3.4B | 2.62B | 2.8B | 2.54B | 2.8B | 2.05B | 2.23B | 16.55B | 16.44B | 16.89B | 1.17B | 2.9B |
| Net Interest Income | -2.36B | -2.25B | -2.06B | -1.94B | -1.74B | -1.53B | -1.56B | -1.84B | -1.76B | -1.67B | -1.6B | -1.54B | -1.61B | -1.72B | -1.68B | -1.7B | -2.1B | -1.64B | -2.02B | -2.21B | -955M | -655M | -563M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2.36B | 2.25B | 2.06B | 1.94B | 1.74B | 1.53B | 1.56B | 1.84B | 1.76B | 1.67B | 1.6B | 1.54B | 1.61B | 1.72B | 1.68B | 1.7B | 2.1B | 1.64B | 2.02B | 2.21B | 955M | 655M | 563M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -2.25B | -2.13B | -2.02B | -1.92B | -473M | 155M | -1.83B | -1.97B | -1.31B | -1.68B | -1.39B | -2.01B | -2.08B | -1.85B | -1.92B | -777M | -1.93B | -1.8B | -1.76B | -1.76B | -1.17B | -755M | -743M | -641M | -594M | -720M | -16.04B | -15.21B | -15.81B | -783M | -456M |
| Pretax Income | 9.82B | 9.83B | 8.52B | 7.71B | 8.58B | 9.83B | 5.43B | 5.24B | 5.33B | 4.38B | 4.81B | 3.96B | 3.48B | 2.95B | 2.89B | 3.56B | 2.23B | 2B | 1.17B | 1.19B | 1.66B | 2.15B | 1.97B | 2.16B | 1.46B | 1.5B | 516M | 1.23B | 1.08B | 388M | 2.44B |
| Pretax Margin % | 12.48% | 13.01% | 12.07% | 11.86% | 14.24% | 16.74% | 10.54% | 10.22% | 11.43% | 10.04% | 11.59% | 9.97% | 9.43% | 8.62% | 8.77% | 10.95% | 7.27% | 6.66% | 4.12% | 4.43% | 6.52% | 8.79% | 8.39% | 9.89% | 7.37% | 8.38% | 3.1% | 7.37% | 5.79% | 2.06% | 12.27% |
| Income Tax | 2.02B | 2.05B | 1.87B | 1.61B | 1.75B | 2.11B | 1.04B | 1.1B | 946M | 1.64B | 1.38B | 1.26B | 1.11B | 950M | 888M | 719M | 658M | 627M | 268M | 316M | 626M | 725M | 727M | 824M | 622M | 602M | 297M | 570M | 549M | 206M | 981M |
| Effective Tax Rate % | 20.6% | 20.85% | 21.89% | 20.96% | 20.35% | 21.48% | 19.21% | 20.96% | 17.73% | 37.39% | 28.65% | 31.87% | 31.83% | 32.25% | 30.68% | 20.19% | 29.49% | 31.32% | 22.91% | 26.55% | 37.67% | 33.74% | 36.85% | 38.22% | 42.75% | 40% | 57.56% | 46.45% | 50.79% | 53.09% | 40.17% |
| Net Income | 6.78B | 6.78B | 5.76B | 5.24B | 5.64B | 6.96B | 3.75B | 3.5B | 3.79B | 2.22B | 2.89B | 2.13B | 1.88B | 1.56B | 1.6B | 2.46B | 1.21B | 1.05B | 673M | 874M | 1.04B | 1.42B | 1.25B | 1.33B | 833M | 886M | 292M | 740M | 471M | -305M | 1.5B |
| Net Margin % | 8.61% | 8.97% | 8.16% | 8.07% | 9.37% | 11.84% | 7.28% | 6.83% | 8.11% | 5.08% | 6.97% | 5.37% | 5.08% | 4.55% | 4.86% | 7.58% | 3.93% | 3.51% | 2.37% | 3.25% | 4.07% | 5.82% | 5.3% | 6.11% | 4.22% | 4.94% | 1.75% | 4.44% | 2.52% | -1.62% | 7.56% |
| Net Income Growth % | 6.81% | 17.78% | 9.88% | -7.11% | -18.88% | 85.3% | 7.1% | -7.45% | 70.89% | -23.32% | 35.74% | 13.55% | 20.5% | -3.05% | -34.89% | 104.23% | 14.52% | 56.61% | -23% | -15.64% | -27.25% | 14.29% | -6.46% | 59.9% | -5.98% | 203.42% | -60.54% | 57.11% | 254.43% | -120.27% | 56.61% |
| Net Income (Continuing) | 7.8B | 7.78B | 6.66B | 6.09B | 6.83B | 7.72B | 4.39B | 4.14B | 4.39B | 2.74B | 3.43B | 2.7B | 2.37B | 2B | 2.01B | 2.84B | 1.57B | 1.38B | 902M | 874M | 1.04B | 1.42B | 1.25B | 1.48B | 981M | 903M | 208M | 683M | 401M | 182M | 1.46B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -153M | -431M | 44M |
| Minority Interest | 3.48B | 3.26B | 3.05B | 2.83B | 2.69B | 2.42B | 2.32B | 2.24B | 2.03B | 1.81B | 1.67B | 1.55B | 1.4B | 1.34B | 1.32B | 1.24B | 1.13B | 1.01B | 995M | 938M | 907M | 828M | 809M | 680M | 611M | 563M | 572M | 763M | 765M | 836M | 836M |
| EPS (Diluted) | 31.20 | 28.38 | 22.00 | 18.96 | 19.15 | 21.16 | 10.93 | 10.07 | 10.66 | 5.95 | 7.30 | 4.99 | 4.16 | 3.37 | 3.49 | 4.97 | 2.76 | 3.02 | 1.93 | 2.51 | 2.53 | 3.18 | 2.58 | 2.61 | 1.59 | 1.65 | 0.40 | 1.11 | 0.73 | -0.46 | 2.22 |
| EPS Growth % | 16.66% | 29% | 16.03% | -0.99% | -9.5% | 93.6% | 8.54% | -5.53% | 79.16% | -18.49% | 46.29% | 19.95% | 23.44% | -3.44% | -29.78% | 80.07% | -8.61% | 56.48% | -23.11% | -0.79% | -20.44% | 23.26% | -1.15% | 64.15% | -3.64% | 312.5% | -63.96% | 52.05% | 258.7% | -120.72% | 55.24% |
| EPS (Basic) | - | 28.62 | 22.27 | 19.24 | 19.44 | 21.51 | 11.08 | 10.27 | 11.04 | 6.33 | 7.80 | 5.34 | 4.46 | 3.54 | 3.62 | 5.17 | 2.83 | 3.08 | 1.97 | 2.56 | 2.57 | 3.24 | 2.62 | 2.66 | 1.63 | 1.69 | 0.39 | 1.12 | 0.73 | -0.46 | 2.24 |
| Diluted Shares Outstanding | 217.21M | 230.71M | 261.81M | 276.41M | 294.67M | 328.75M | 345.37M | 348.23M | 355.3M | 372.22M | 395.85M | 426.72M | 450.35M | 461.91M | 459.4M | 495.94M | 437.35M | 348.71M | 348.71M | 348.71M | 410.2M | 447.5M | 483.66M | 510.34M | 523.9M | 536.97M | 553.93M | 666.67M | 645.21M | 663.04M | 677.93M |
| Basic Shares Outstanding | 222.2M | 230.71M | 258.6M | 272.4M | 290.35M | 323.31M | 339.43M | 341.21M | 342.9M | 350.09M | 370.54M | 398.74M | 420.48M | 439.6M | 443.2M | 476.61M | 426.42M | 341.93M | 341.93M | 341.93M | 403.4M | 440.02M | 475.62M | 500.75M | 511.04M | 524.26M | 547.51M | 660.71M | 645.21M | 663.04M | 671.88M |
| Dividend Payout Ratio | - | 10.01% | 11.98% | 12.61% | 11.57% | 8.97% | 4.08% | 15.69% | 12.86% | - | - | - | 0.37% | 1.03% | 196.14% | 1.26% | 352.69% | - | - | - | 19.4% | 18.12% | 15.97% | 2.93% | 4.8% | 4.74% | 15.07% | - | - | - | 3.59% |
Quick answers to the most common questions about buying HCA stock.
For fiscal year 2025, HCA Healthcare, Inc. (HCA) reported total revenue of $75.60B. This represents a 279.7% increase compared to $19.91B in 1996.
HCA Healthcare, Inc. (HCA) is profitable, generating $6.78B in net income for the fiscal year ending 2025 with a net profit margin of 9.0%.
HCA Healthcare, Inc. (HCA) reported an operating income of $11.96B, resulting in an operating profit margin of 15.8%. This margin reflects the operational efficiency of the business before interest and taxes.
HCA Healthcare, Inc. (HCA) generated $31.37B in gross profit for the year, representing a gross profit margin of 41.5%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Labor cost and reimbursement pressure
Metrics are mathematically derived from official filings.
Revenue Growth Moderating Toward Mid-Single Digits
Based on reported quarterly figures, HCA's revenue growth slowed from 10.3% in Q2 2024 to 3.6% in Q3 2026, suggesting the high-single-digit volume recovery of the prior cycle is losing momentum.
The deceleration from double-digit growth to low-single digits suggests volume gains are normalizing rather than compounding. Investors should monitor whether same-facility admissions and case mix can sustain top-line expansion without relying on pricing. The data does not isolate organic versus acquired growth, which limits conclusions about underlying durability.
Reported Margin Structure Requires Reclassification Context
Reported gross margin fell from roughly 41% through 2025 to about 15% in 2026 quarters, a shift that appears driven by a change in how cost lines are presented rather than by an observable operating deterioration.
Operating margin tracks gross margin almost exactly in the 2026 periods, which is consistent with a reporting reclassification that moved costs into a different line. Treating the drop as economic compression would likely overstate the deterioration. Comparability against peers such as Tenet and Universal Health Services should be verified against consistent line definitions before drawing margin conclusions.
EPS Growth Outpaces Net Income Trend
Based on EDBL-style reported figures, diluted EPS rose 44.6% year over year in Q4 2025 while revenue grew only 6.7%, indicating buybacks and share count reduction likely contributed materially to per-share results.
The gap between EPS and net income growth suggests repurchase activity is a meaningful driver of per-share earnings. In Q2 2026 EPS of $7.62 beat the cited $6.78 expectation, but the lowered full-year guidance tempers how much weight that single quarter should carry. Stock-based compensation is largely absent from the reported 2026 data, so its impact on earnings quality cannot be assessed for those periods.
Guidance Cut Undercuts Headline Beat
As reported in recent filings, the Q2 2026 EPS beat of $7.62 against $6.78 expected was paired with a full-year guidance reduction, which may signal decelerating momentum in the back half of the year.
A headline beat followed by lower forward guidance is a pattern bears typically cite as evidence of one-time strength masking weaker trends. The risk is that operating leverage visible in prior quarters reverses if labor costs or payor mix shift unfavorably. Site-neutral payment proposals add a policy overhang that could compress outpatient pricing, which warrants further investigation.